ABSTRACT
Understanding the interplay between antibiotic resistance and bacterial fitness and virulence is essential to guide individual treatments and improve global antibiotic policies. A paradigmatic example of a resistance mechanism is the intrinsic inducible chromosomal β-lactamase AmpC from multiple Gram-negative bacteria, including Pseudomonas aeruginosa, a major nosocomial pathogen. The regulation of ampC expression is intimately linked to peptidoglycan recycling, and AmpC-mediated β-lactam resistance is frequently mediated by inactivating mutations in ampD, encoding an N-acetyl-anhydromuramyl-l-alanine amidase, affecting the levels of ampC-activating muropeptides. Here we dissect the impact of the multiple pathways causing AmpC hyperproduction on P. aeruginosa fitness and virulence. Through a detailed analysis, we demonstrate that the lack of all three P. aeruginosa AmpD amidases causes a dramatic effect in fitness and pathogenicity, severely compromising growth rates, motility, and cytotoxicity; the latter effect is likely achieved by repressing key virulence factors, such as protease LasA, phospholipase C, or type III secretion system components. We also show that ampC overexpression is required but not sufficient to confer the growth-motility-cytotoxicity impaired phenotype and that alternative pathways leading to similar levels of ampC hyperexpression and resistance, such as those involving PBP4, had no fitness-virulence cost. Further analysis indicated that fitness-virulence impairment is caused by overexpressing ampC in the absence of cell wall recycling, as reproduced by expressing ampC from a plasmid in an AmpG (muropeptide permease)-deficient background. Thus, our findings represent a major step in the understanding of β-lactam resistance biology and its interplay with fitness and pathogenesis.
IMPORTANCE
Understanding the impact of antibiotic resistance mechanisms on bacterial pathogenesis is critical to curb the spread of antibiotic resistance. A particularly noteworthy antibiotic resistance mechanism is the β-lactamase AmpC, produced by Pseudomonas aeruginosa, a major pathogen causing hospital-acquired infections. The regulation of AmpC is linked to the cell wall recycling pathways, and frequently, resistance to β-lactams is caused by mutation of several of the components of the cell wall recycling pathways such as AmpD. Here we dissect the impact of the pathways for AmpC hyperproduction on virulence, showing that the lack of all three P. aeruginosa AmpD amidases causes a major effect in fitness and pathogenicity, compromising growth, motility, and cytotoxicity. Further analysis indicated that fitness-virulence impairment is specifically caused by the hyperproduction of AmpC in the absence of cell wall recycling. Our work provides valuable information for delineating future strategies for combating P. aeruginosa infections by simultaneously targeting virulence and antibiotic resistance.
INTRODUCTION
Continuously increasing antimicrobial resistance, added to the limited development of new antibiotics, is of growing concern since it severely compromises our therapeutic arsenal to fight life-threatening bacterial infections (1). Understanding the interplay between antibiotic resistance and bacterial fitness and virulence is thus of paramount relevance for guiding individual treatments and global antibiotic policies. While there is a well-established body of evidence indicating that generally antibiotic resistance is associated with a biological cost, an enormous variability of the cost has been reported, depending on the antibiotic, pathogen, or genetic context (2, 3). Moreover, in many instances, the precise factors driving the fitness effects remain elusive. Likewise, reduced fitness is expected to directly impair bacterial virulence, but the interplay between virulence and antibiotic resistance is far more complex, including regulatory circuits controlling both traits (4, 5).
Resistance by modification of an antibiotic target such as DNA gyrase (quinolones) or the β subunit of RNA polymerase (rifampin) is frequently associated with a direct biological cost, but the basis underlying the fitness and virulence effects associated with the resistance due to detoxifying mechanisms such as efflux pumps, or antibiotic-inactivating enzymes (like β-lactamases) is far more complex and controversial (2, 6). Potential explanations range from the simple energetic cost of expressing the resistance mechanisms to direct mechanistic side effects (such as extrusion of compounds relevant for cell physiology or virulence by efflux pumps or the modification of cell components by antibiotic-inactivating enzymes) or indirect effects produced by the specific mutations (generally in regulatory genes) leading to the expression of the resistance mechanisms.
A complex example is the intrinsic inducible chromosomal β-lactamase AmpC from multiple Gram-negative rods, including most enterobacteria and Pseudomonas aeruginosa, a major nosocomial pathogen considered a paradigmatic model of antimicrobial resistance and virulence (7, 8). Mutational overexpression of ampC is a very frequent cause of resistance to the antipseudomonal penicillins and cephalosporins (9, 10).
Multiple genes are involved in the regulation of ampC expression, a process that is intimately linked to peptidoglycan recycling (11, 12). The ampG gene encodes an inner membrane permease for GlcNAc-1,6-anhydromuropeptides, which are peptidoglycan catabolites that, upon entry into the cytosol, are processed by the β-N-acetylglucosaminidase NagZ to generate 1,6-anhydromuropeptides (13, 14). The 1,6-anhydromuropeptide products of NagZ are thought to induce AmpC production by interacting with the LysR-type transcriptional regulator AmpR (15–17). During bacterial growth, 1,6-anhydromuropeptides are processed by the N-acetyl-anhydromuramyl-l-alanine amidase AmpD, avoiding ampC induction (18). During growth in the presence of strong β-lactamase inducers (such as carbapenems), large amounts of muropeptides are generated and accumulate in the cytoplasm which leads to AmpR-mediated induction of ampC expression (16, 17). Mutational inactivation of AmpD also leads to the accumulation of 1,6-anhydromuropeptides and to ampC hyperexpression, even in the absence of β-lactamase inducers, resulting in a constitutively derepressed resistance phenotype due to AmpC overproduction (9, 19). Further studies showed that P. aeruginosa has, in addition to the cytoplasmic AmpD, two periplasmic N-acetyl-anhydromuramyl-l-alanine amidases (AmpDh2 and AmpDh3) and that their sequential inactivation leads to a stepwise upregulation of ampC, reaching full derepression with very high levels (>1,000-fold with respect to the wild-type level) of ampC expression and clinical β-lactam resistance in the triple mutant (20). This full ampC derepression through inactivation of the three amidases has been associated with fitness and virulence impairment (21).
More-recent work showed that one-step clinical resistance in P. aeruginosa frequently results from the inactivation of dacB encoding the nonessential penicillin-binding protein 4 (PBP4) (22). The dd-carboxypeptidase and endopeptidase PBP4 has been shown to play a sentinel role for cell wall damage by β-lactams, producing a complex resistance response, triggering overproduction of the chromosomal β-lactamase AmpC and specific activation of the CreBC (BlrAB) two-component regulator (23–26). Moreover, the ampC transcriptional regulator AmpR has been shown to have global regulatory functions, including several virulence genes (27). Illustrative schemes of the complex ampC regulation pathways have been published previously (12, 22).
Altogether, the mentioned studies suggest that an interplay between ampC regulation, β-lactam resistance, cell wall recycling, fitness, and virulence might exist. However, the available information is disperse and limited, failing to clarify key aspects such as whether overexpression of ampC (the mechanism) or the blocking of peptidoglycan recycling (the pathway) is impacting fitness and virulence or whether it is restricted to an energy burden matter or, alternatively, to specific virulence responses. Using the two reference P. aeruginosa strains PAO1 and PA14, we demonstrate that the lack of all three AmpD amidases has a major effect on fitness and pathogenicity, severely compromising growth rates, motility, and cytotoxicity, the latter being likely due to repression of key virulence factors. Moreover, we show that ampC overexpression is required but not sufficient to confer the growth-motility-cytotoxicity impaired phenotype (GMC phenotype) and that alternative pathways such as those involving PBP4, leading to similar levels of ampC hyperexpression and β-lactam resistance avoid any defect in fitness or virulence. Finally, we demonstrate that the fitness-virulence impairment is due to overexpression of ampC in the absence of cell wall recycling, as reproduced when expressing ampC from a plasmid in an AmpG (muropeptide permease)-deficient background. Thus, our results elucidate a major pathway to β-lactam resistance side effects to the bacterial host and how they could contribute to the development of strategies for combating P. aeruginosa infections.
RESULTS
Overview of ampC derepression pathways.
Table 1 shows a comparative analysis of the effects on β-lactam resistance and ampC expression produced by single or multiple mutations in the genes ampD, ampDh2, and ampDh3 for the three peptidoglycan-recycling amidases and/or dacB for PBP4 in P. aeruginosa reference strains PAO1 and PA14. Results for strain PAO1, in agreement with previous data (20, 22, 28), confirmed a stepwise increase of β-lactam MICs and ampC expression by inactivation of the three amidases, reaching high-level resistance and ampC values approximately 1,000-fold above the wild-type values in the triple mutant. The ampC expression levels and β-lactam MICs were slightly higher for the ampD dacB double mutant (Table 1). Overall, the results for strain PA14 followed the same trend with some differences. Basal expression of ampC in PA14 was slightly higher than in PAO1 but was much less responsive to mutation in ampD or dacB. Double ampD ampDh3 inactivation in PA14 produced a major effect on ampC expression (approximately 1,000-fold increase), which was not much further increased in the ampD triple mutant. The impact on β-lactam resistance and ampC expression of the ampD dacB double mutant was lower than that of PAO1. In summary, similar >1,000-fold increases in ampC expression levels were obtained in the ampD ampDh2 ampDh3 triple mutant and ampD dacB double mutant of PAO1 and in the ampD ampDh2 ampDh3 triple mutant and ampD ampDh3 double mutant of PA14 (Table 1).
TABLE 1 .
Strain | MIC (µg/ml)a |
Avg level of ampC expression ± SDb | |||||||
---|---|---|---|---|---|---|---|---|---|
CAZ | FEP | PIP-TZ | ATM | IMP | MER | VAN | COL | ||
PAO1 | 1 | 1 | 4 | 1 | 1.5 | 0.38 | 512 | 0.75 | 1 |
PAΔD | 6 | 4 | 64 | 6 | 1.5 | 1 | 512 | 0.75 | 63.3 ± 7.1 |
PAΔDDh2 | 16 | 12 | 96 | 16 | 1.5 | 1 | 512 | 0.75 | 79.5 ± 12.2 |
PAΔDDh3 | 48 | 32 | >256 | 16 | 1.5 | 2 | 512 | 0.75 | 251.2 ± 51.9 |
PAΔDDh2Dh3 | 48 | 32 | >256 | 32 | 1.5 | 2 | 512 | 0.75 | 1,225 ± 101 |
PAΔDDh2Dh3 + pUCPAD | 1.5 | 1.5 | 6 | 1.5 | 1 | 0.5 | 512 | 0.75 | 2.9 ± 0.7 |
PAΔdacB | 32 | 12 | 96 | 16 | 1.5 | 0.5 | 512 | 0.75 | 53 ± 22.2 |
PAΔdacBΔD | 128 | 64 | >256 | 48 | 2 | 2 | 512 | 0.75 | 1,770 ± 401 |
PAΔAG | 1 | 1 | 3 | 1 | 0.38 | 0.38 | 512 | 0.75 | −1.1 ± 0.4 |
PAO1 + pUCPAC | 24 | 16 | 96 | 16 | 1.5 | 1.5 | 512 | 0.75 | 1,925.5 ± 514 |
PAΔAG + pUCPAC | 24 | 16 | 96 | 16 | 1.5 | 1.5 | 512 | 0.75 | 1,480 ± 359.1 |
PA14 | 0.75 | 0.5 | 3 | 1 | 1 | 0.125 | 512 | 0.25 | 5.2 ± 2.9 |
PA14ΔD | 1.5 | 1.5 | 4 | 3 | 1 | 0.19 | 512 | 0.25 | 8.9 ± 1.5 |
PA14ΔDh2 | 0.75 | 0.5 | 3 | 1 | 1 | 0.125 | 512 | 0.25 | 5.1 ± 1.2 |
PA14ΔDh3 | 0.75 | 0.5 | 3 | 1 | 1 | 0.125 | 512 | 0.25 | 4.5 ± 2.2 |
PA14ΔDh2Dh3 | 1 | 0.5 | 3 | 1 | 1 | 0.19 | 512 | 0.25 | 4.7 ± 1.5 |
PA14ΔDDh2 | 1 | 0.75 | 4 | 1.5 | 1 | 0.125 | 512 | 0.25 | 12 ± 2.1 |
PA14ΔDDh3 | 16 | 8 | 128 | 16 | 1 | 1.5 | 512 | 0.25 | 4,561 ± 570 |
PA14ΔDDh2Dh3 | 16 | 8 | >256 | 24 | 1.5 | 1.5 | 512 | 0.25 | 5,569 ± 928 |
PA14ΔDDh2Dh3 + pUCPAD | 2 | 1.5 | 6 | 3 | 1 | 0.25 | 512 | 0.25 | 152.2 ± 77.1 |
PA14ΔdacB | 4 | 3 | 8 | 4 | 1 | 0.19 | 512 | 0.25 | 36 ± 10.2 |
PA14ΔdacBΔD | 8 | 6 | 96 | 12 | 1 | 0.25 | 512 | 0.25 | 114.1 ± 42.1 |
Abbreviations: CAZ, ceftazidime; FEP, cefepime; PIP-TZ, piperacillin-tazobactam; ATM, aztreonam; IMP, imipenem; MER, meropenem; VAN, vancomycin; COL, colistin.
Relative amount of ampC mRNA compared to the amount expressed in strain PAO1.
Impact of AmpC hyperproduction on growth rate and motility: not only a matter of metabolic cost.
In order to evaluate the potential fitness cost associated with AmpC hyperproduction and/or blocking of peptidoglycan recycling, the growth rates of the mutants discussed below were determined (Fig. 1). The simultaneous inactivation of the three amidases increased the doubling times of both PAO1 (49.9 min versus 30.1 min in the wild type) and PA14 (54.7 min versus 36.4 min in the wild type). Growth curves of the relevant strains are shown in Fig. S1 in the supplemental material. AmpC overexpression was required for the growth impairment, since knocking out ampC in the triple ampD mutant fully restored the wild-type growth rate for both PAO1 and PA14 strains. Likewise, trans-complementation with wild-type ampD also restored the wild-type growth rate. However, AmpC overexpression per se did not have a major impact on growth rates, since the ampD dacB and ampD ampDh3 double mutants with similar ampC hyperexpression levels had the same generation times as strains PAO1 and PA14, respectively (Fig. 1). It can be deduced from these results that impaired peptidoglycan recycling and accumulation of muropeptides caused by the lack of amidase activity in the ampD triple mutant do not have a significant effect on growth rates. We next examined whether AmpC hyperproduction and/or blocking of peptidoglycan recycling affected bacterial motility. As for growth rates, inactivation of the three amidases had a substantial effect on the three types of motility, including twitching (Fig. 2), swimming (Fig. 3), and swarming (Fig. 4). The results were identical for PAO1 and PA14 derivatives; the only exception was that twitching could not be evaluated in PAO1 derivatives since the wild-type strain is defective in this type of motility. Again, ampC overexpression was required for the motility impairment, as knocking out ampC in the ampD triple mutant restored wild-type motility. Likewise, trans-complementation with wild-type ampD also restored the wild-type motility. However, ampC overexpression did not have a major effect on bacterial motility since the ampC hyperexpressing ampD dacB and ampD ampDh3 double mutants had wild-type twitching, swimming, and swarming. Again, these results indicated that impaired peptidoglycan recycling and accumulation of muropeptides caused by lack of amidase activity in the ampD triple mutant do not have a significant effect on bacterial motility per se.
Thus, the very high-level ampC overexpression (>1,000-fold compared to the wild-type value) has a major impact on growth rate and motility, but only if it is associated with an amidase-deficient background. In other words, ampC overexpression is necessary but not sufficient for the observed growth- and motility-impaired phenotype, indicating a capital role of the pathway involved.
Pathway-dependent effect of ampC derepression on virulence.
We next analyzed whether AmpC hyperproduction and/or blocking of peptidoglycan recycling affects bacterial virulence in the Galleria mellonella killing assay (Fig. 5). The 50% lethal dose (LD50) of strain PA14 (ca. 2 CFU) is lower than that of strain PAO1 (ca. 18 CFU) due to the higher virulence of the former (29, 30). Inactivation of the three amidases produced a major increase (approximately 12-fold) of the LD50 of strain PAO1 (Fig. 5A), and the increase was much higher (approximately 110-fold) for the triple mutant of strain PA14. Interestingly, despite the major virulence difference of the wild-type strains, the PAO1 and PA14 triple amidase mutants had similar LD50s. As for growth rate and motility, wild-type virulence was restored upon inactivation of ampC and through trans-complementation with wild-type ampD. Thus, the effect was specific to the triple amidase mutants since the ampD dacB or ampD ampDh3 mutants showed wild-type virulence, except for a very modest increase in the LD50 of the PA14 ampD-ampDh3 mutant (Fig. 5B).
ampC derepression does not cause major changes in cell envelope physiology.
To examine whether the effects on growth rates, motility, and virulence of the inactivation of the three P. aeruginosa amidases was a consequence of a modification of the cell envelope or related structures, wild-type PAO1 and its triple amidase mutant were analyzed by electron microscopy (see Fig. S2 in the supplemental material). Negative staining (Fig. S2A and B) showed no differences in the presence and width of flagella, whereas scanning electron microscopy (SEM) (Fig. S2C and D) did not reveal differences in cell shape or size. Moreover, the bacterial sections obtained for transmission electron microscopy (TEM) analysis did not show alterations in the morphology and width of the bacterial envelopes (Fig. S2E and F).
Additionally, we analyzed whether inactivation of the three amidases could modify the susceptibility to colistin, which targets the bacterial surface, or vancomycin, which targets the cell wall with an activity highly affected by the level of peptidoglycan cross-linking (23). Nevertheless, as shown in Table 1, colistin and vancomycin MICs were identical against mutant and wild-type strains. The only difference was that strain PAO1 (and derivatives) showed higher colistin MICs than strain PA14 did.
We next examined whether inactivation of the three amidases weakens the peptidoglycan, making the host more susceptible to killing by immune system components targeting the bacterial surface, such as the complement or neutrophils. To evaluate complement-mediating killing, strains PAO1 and PA14 and their respective triple amidase mutants were incubated with nonimmune human serum (NHS) and heat-inactivated nonimmune human serum (HI-NHS). Results shown in Fig. S3 in the supplemental material evidenced that strain PAO1 is more resistant to complement-mediated killing than strain PA14 is but revealed no differences between mutant and wild-type strains. To evaluate neutrophil killing, the percentages of bacterial survival after coincubation with freshly purified neutrophils was assessed, and the results are also shown in Fig. S3. However, no significant differences were found when comparing each wild-type strain with its corresponding triple amidase mutant, reaching in all cases a high rate of neutrophil-mediated bacterial death, close to 95%. Finally, when using HI-NHS instead of NHS, a general decrease in neutrophil bactericidal activity was observed as expected, given the almost complete reduction in opsonization capacity that heat inactivation causes in the complement cascade, but once more, no differences between wild-type and mutant strains were found.
Cytotoxicity is specifically impaired by pathway-dependent ampC derepression.
We next analyzed whether the observed effect on virulence could also be caused by a decreased invasiveness or cytotoxicity mediated by ampC overexpression and/or blocking of peptidoglycan recycling. For this purpose, wild-type strains PAO1 (model invasive strain) and PA14 (model cytotoxic strain) and mutant derivatives were tested.
To evaluate invasion capacity, A549 human type II alveolar epithelial cells were challenged with wild-type strain PAO1 or its triple amidase mutant, and the numbers of intracellular bacteria were assessed after 3 h of coincubation. However, as shown in Fig. 6A, no differences on intracellular bacteria numbers were found between strain PAO1 and the mutant. Invasion capacity could not be assessed for strain PA14, since fast cell lysis produced by this highly cytotoxic strain precluded the accurate quantification of intracellular bacteria.
On the other hand, cytotoxicity was evaluated in strain PA14 and derivatives through the quantification of lactate dehydrogenase (LDH) release in culture supernatants (Fig. 6B). Interestingly, cytotoxicity was nearly fully abolished in the triple amidase mutant. Moreover, once more, cytotoxicity was restored upon ampC inactivation or trans-complementation with wild-type ampD. Likewise, the effect was specific to the triple amidase mutant, since the ampD dacB mutant showed wild-type cytotoxicity and the ampD ampDh3 mutant displayed only a slight reduction (Fig. 6B). To rule out the possibility that the abolishment of cytotoxicity could be a consequence of the mentioned reduced motility, the assays were repeated after adding a plate centrifugation step to ensure close contact between bacterial and epithelial cells, but as can be observed in Fig. 6B, the same results were obtained. Additionally, the LDH assays were also performed with PAO1 derivatives and despite the very low cytotoxicity of this strain, the same trend was evidenced (Fig. 6C).
Finally, to address whether the triple amidase inactivation could trigger effects changing the proinflammatory capacity of the peptidoglycan, we analyzed the interleukin 8 (IL-8) release in A549 cell cultures during coincubation with different stimuli. However, IL-8 release was not modified in the mutant strains compared to the wild-type strain (PAO1 or PA14) when using either intact cells (see Fig. S4A in the supplemental material), cell-free bacterial culture supernatants (Fig. S4B), or purified peptidoglycans (Fig. S4C). The only remarkable difference was that IL-8 release was higher when using PAO1 purified peptidoglycan compared to PA14 and the other way around for cell-free culture supernatants.
Global transcriptomics reveals major specific effects of pathway-dependent ampC derepression on virulence gene expression.
We next analyzed whether the observed fitness and virulence effects could be consequences of modified gene expression. For this purpose, we performed a global transcriptomic analysis of the triple ampD mutant compared to strain PAO1 using the Affymetrix gene chips. Up to 81 genes showed a modified (≥2-fold) expression; 47 genes were upregulated, and 34 were downregulated (see Table S1 in the supplemental material). Upregulated genes obviously included ampC, but most other genes fell within the energy metabolism category and thus could be related to the lower growth rate of the ampD triple mutant. On the other hand, downregulated genes were significantly enriched in virulence genes. Indeed, downregulated genes included, among others, lasA (protease), plcB (phospholipase C), the pilM-pilQ operon (type IV pili), wbpL and wbpH (lipopolysaccharide [LPS] biosynthesis), and seven genes (pcrV, pcrH, popB, popD, pscE, pscH, and pscI) related to the type III secretion system (TTSS). Moreover, the level of expression of exoS, encoding a key cytotoxin secreted by the TTSS, was 1.9-fold lower in the triple ampD mutant than in wild-type PAO1.
To confirm and expand these results, we next analyzed the expression of six key selected virulence genes (lasA, plcB, pilM, pcrV, pscH, and exoS or exoU) through reverse transcription-PCR (RT-PCR) in wild-type strains PAO1 (Fig. 7) and PA14 (see Fig. S5 in the supplemental material) and their respective mutant derivatives. As can be observed, downregulation of all these genes was confirmed for the PAO1 ampD triple mutant (Fig. 7) and also evidenced for the PA14 ampD triple mutant using in this case exoU instead of exoS (Fig. S5). Moreover, as mentioned above, inactivation of ampC and trans-complementation with a wild-type ampD gene restored wild-type expression. Likewise, overexpression of ampC caused by ampD dacB inactivation did not modify virulence gene expression, while the ampD ampDh3 double amidase mutant had only a modest effect on expression of some of the virulence genes (Fig. 7; Fig. S5).
Dissection of the underlying basis for the pathway-dependent impact of ampC derepression on fitness and virulence.
Results obtained so far clearly indicated that very high-level ampC expression (>1,000-fold compared to the wild-type value) has a major impact on fitness and virulence, but only if occurring in an amidase-deficient background. Since amidase activity is required for peptidoglycan turnover, we hypothesized that the observed effect could be caused by overexpressing ampC in the absence of cell wall recycling. To test this hypothesis, we first analyzed the individual effect of blocking of peptidoglycan recycling by using an ampG mutant of strain PAO1 and the individual effect of ampC overexpression by introducing into PAO1 a plasmid-encoded ampC gene (pUCPAC), providing expression levels similar to that of the ampD triple mutant (approximately 1,500-fold increased expression [Table 1]). Indeed, as can be observed in Fig. 8, neither inactivation of ampG nor overexpression of a plasmid-mediated ampC significantly modified fitness (doubling time) or virulence (G. mellonella lethality) of strain PAO1. However, when both features were gathered together in the PAO1 ampG mutant expressing the plasmid-mediated ampC gene, a major effect on fitness and virulence was evidenced (Fig. 8), proving the established hypothesis.
Moreover, other potential hypotheses that could have eventually explained the different behavior of the ampD triple mutant compared to other mutants showing similar levels of AmpC expression (such as the ampD dacB double mutant) were ruled out. These hypotheses included a potential differential effect on ampR expression, which was ruled out since the transcription of this gene was not modified in any of the mutants (see Fig. S6 in the supplemental material). Besides, as expected, knocking down ampG or ampR in the triple amidase mutant abolished ampC overexpression and consequently restored wild-type fitness and virulence phenotype (Fig. 8). Finally, we also ruled out the possibility that the preservation of fitness and virulence of the dacB mutants was driven by the previously documented activation of the creBC system (28), since knocking down this two-component regulatory system did not produce a significant effect on fitness and virulence (Fig. 8).
DISCUSSION
In this work, we show that the lack of the three P. aeruginosa N-acetyl-anhydromuramyl-l-alanine amidases causes a dramatic effect in fitness, severely compromising growth rates and bacterial motility (twitching, swimming, and swarming). Moreover, cytotoxicity, but not invasiveness, is specifically impaired in the triple amidase mutant, likely due to the repression of key virulence factors such as the protease LasA, phospholipase C, or TTSS components. Moreover, the inactivation of the three amidases in both PAO1 and PA14 strains significantly increased LD50s in the G. mellonella model. It is noteworthy that the higher pathogenicity of strain PA14 compared to the pathogenicity of strain PAO1 (30) was fully abolished upon disruption of N-acetyl-anhydromuramyl-l-alanine amidase activity; in other words, while LD50s were much lower for strain PA14 than for strain PAO1, the LD50s of the corresponding amidase triple mutants were much higher but nearly identical in both mutants. This is likely explained by the fact that the higher virulence of PA14 mainly relies on its potent cytotoxicity (related to ExoU production and an elevated TTSS activity [30, 31]), and cytotoxicity is specifically impaired in the triple amidase mutant. In other words, although the reduced growth rates may largely explain the reduced pathogenicity, the specific impairment of cytotoxicity is also very relevant for the virulence-attenuated phenotype, especially in the case of PA14.
Likely, the most simple explanation for the observed GMC phenotype would be that the very high level of ampC expression determines a major energetic burden compromising cell physiology and, consequently, fitness and virulence. Indeed, this hypothesis would be supported by the fact that knocking out ampC in the ampD triple mutant fully restored the wild-type phenotype. However, the level of ampC overexpression by itself does not explain the GMC phenotype, since similar levels are also produced through alternative pathways, such as the double inactivation of ampD and dacB genes, which does not affect fitness or virulence. Thus, so far we could conclude that the very high level of ampC overexpression was required but not sufficient for the observed GMC phenotype. Alternatively to the hypothesis of energetic burden of ampC expression, the activity of AmpC itself could have an effect on cell physiology. Indeed, AmpC and other β-lactamases may modify the structure of the peptidoglycan, due to residual dd-peptidase activity reminiscent of their PBP ascendance (32, 33). In any case, activity of AmpC by itself would still be necessary but not sufficient to produce the GMC phenotype, since as discussed above, alternative paths leading to similar levels of ampC overexpression do not show altered fitness or virulence. Thus, our data suggest that ampC overexpression and the peptidoglycan alterations produced by the specific mutations should act in concert to confer the observed GMC phenotype.
We have previously shown that ampC overexpression driven by both ampD and dacB inactivation requires a functional AmpG and an activated AmpR (22, 34). Thus, although there is evidence supporting the hypothesis that AmpG or AmpR may play a role in virulence (4, 27, 35), they do not affect differentially both ampC overexpression pathways. Moreover, transcription of ampR was not affected in any of the mutants.
AmpD, AmpDh2, and AmpDh3 are the three N-acetyl-anhydromuramyl-l-alanine amidases of P. aeruginosa. AmpD is the cytoplasmic enzyme processing soluble 1,6-anhydromuropeptides for the recycling of peptidoglycan catabolites and avoiding ampC induction (36). AmpDh2 and AmpDh3 are periplasmic enzymes mainly acting directly on the insoluble polymeric sacculus of the peptidoglycan for cell wall remodeling (36, 37). However, they can also process soluble 1,6-anhydromuropeptides but with a lower efficiency than that for AmpD (36–38). Thus, candidates for triggers of the fitness and virulence impairment in the amidase triple mutant would be the accumulation of soluble 1,6-anhydromuropeptides and/or the alteration of cell wall remodeling itself. Indeed, cell wall remodeling has been shown to be relevant for the assembly of flagella and for type III and type VI secretion systems (39–42). Moreover, although our results related to membrane physiology (susceptibility to serum, neutrophil killing, and electron microscopy) failed to reflect any differences between the triple AmpD mutant and wild-type, the possibility of AmpDh2 and/or AmpDh3 deletion affecting to a certain degree the assembly and anchoring of bacterial surface structures cannot be completely ruled out and should be explored further, given the existing evidences in this context (43–45).
As mentioned above, a similar (around 1,000-fold) ampC expression level in the dacB ampD double mutant does not produce a significant fitness or virulence effect. Accumulation of soluble 1,6-anhydromuropeptides should however also be high and similar to the amidase triple mutant, since cytosolic AmpD is, as commented above, the main factor. Moreover, the absence of dacB-encoded PBP4 should also further increase muropentapeptide levels (25). Still, an obvious qualitative difference between the ampD triple mutant and the other mutants is the lack of N-acetyl-anhydromuramyl-l-alanine amidase activity in the former, leading to a complete blocking of peptidoglycan recycling. Indeed, our experiments using an ampG mutant of strain PAO1 and a plasmid-mediated ampC demonstrated that fitness-virulence impairment is produced by the blocking of peptidoglycan recycling and simultaneous ampC overexpression.
Finally, we also ruled out the alternative hypothesis that the preservation of fitness and virulence of the dacB mutants was driven by the previously documented activation of the creBC system (shown to play a major role in fitness and response to β-lactam challenge [22, 26]), since knocking out this two-component regulatory system did not produce a significant effect on fitness and virulence.
Regardless of the underlying mechanisms, our results are helpful to understand the natural occurrence of AmpC-hyperproducing mutants among clinical strains, since while ampD dacB double mutants have been well documented (22, 34), ampD triple mutants have not been reported so far. Another practical lesson from this work is that blocking peptidoglycan recycling (e.g., using AmpG inhibitors) might not only be a useful strategy for combating inducible (AmpR-dependent) β-lactam resistance (46, 47) but also AmpR-independent plasmid-mediated AmpCs, frequently seen in members of the family Enterobacteriaceae (48).
In summary, altogether, our results determine a major step forward for understanding bacterial β-lactam resistance responses and should be helpful for guiding the development of future strategies for combating P. aeruginosa infections.
MATERIALS AND METHODS
Bacterial strains and plasmids.
A list and description of the bacterial strains and plasmids used in this work are shown in Table S2 in the supplemental material. P. aeruginosa single or combined knockout ampD, ampDh2, ampDh3, ampC, or dacB mutants were constructed according to previously described procedures (20, 22) based on the Cre-lox system for gene deletion in P. aeruginosa (49) and confirmed by DNA sequencing. Since ampR is contiguous to ampC, the absence of altered ampR sequence and expression in the ampC mutants was confirmed through DNA sequencing and transcriptional analysis through real-time reverse transcription-PCR (RT-PCR), respectively. The previously constructed plasmid pUCPAD was used for the complementation of selected knockout mutants through electroporation followed by selection in Müller-Hinton agar plates containing 50 mg/liter gentamicin (9).
Global transcriptome analysis.
Three independent replicates of P. aeruginosa strains PAO1 and PAΔDDh2Dh3 (PAO1 with ampD ampDh2 ampDh3 knocked out) were grown at 37°C to an optical density at 600 nm (OD600) of 1 in vigorously shaken 50-ml flasks containing 10 ml of LB broth. The total RNA was isolated using the RNeasy minikit (Qiagen), according to the manufacturer’s instructions. RNA was treated with 2 U of Turbo DNase (Ambion) to remove DNA. Ten micrograms of total RNA was used for cDNA synthesis, fragmentation, labeling, and hybridization according to the Affymetrix GeneChip P. aeruginosa genome array expression analysis protocol. Briefly, random hexamers (Invitrogen) were added to the 10 µg of total RNA, and in vitro-synthesized, polyadenylated transcripts for Bacillus subtilis genes were used as a control as recommended. cDNA was synthesized using Superscript II (Invitrogen) according to the manufacturer’s instructions. The reaction was inactivated at 70°C for 10 min, and after hydrolysis with NaOH and neutralization with HCl, cDNA was purified by using a High Pure PCR product purification kit (Roche). The cDNA was fragmented by DNase I (Thermo Fisher Scientific), and the final 3′ end labeling of the fragmentation products was performed with the GeneChip DNA labeling reagent (Affymetrix) following the recommended Affymetrix protocol.
Arrays were hybridized following the manufacturer’s (Affymetrix) instructions. Signal values were generated by the Affymetrix Expression Console 1.4.1 software program, and normalization of the signal values was performed using the Robust Multichip Analysis (RMA) algorithm (50). Statistical analysis was executed by the Transcriptome Analysis Console 3.0 software (Affymetrix) as described previously (22). Only transcripts showing ≥2-fold increases or decreases and one-way analysis of variance (ANOVA) P values less than 0.05 were considered to be differentially expressed. In all cases, the posterior probability for differential expression (PPDE) was between 0.999 and 1. The expression of selected representative genes was further analyzed using real-time RT-PCR.
Analysis of gene expression.
The relative mRNA levels of selected genes (ampC, exoU, exoS, lasA, pcrV, plcB, pilM, and pscH) were determined by real-time RT-PCR, according to previously described protocols (10, 20). Total RNA was obtained with the RNeasy minikit (Qiagen). Fifty nanograms of purified RNA was used for one-step reverse transcription and real-time PCR using an Illumina Eco real-time PCR system as previously described (20). The rpsL housekeeping gene was used to normalize the expression levels, and the results were always referred to PAO1 or PA14. All RT-PCRs were performed in duplicate, and the mean values of expression from three independent experiments were considered. The primers used are listed in Table S3 in the supplemental material.
Motility assays.
The swimming, swarming, and twitching motilities were determined in the selected strains as described previously (51) in plates containing different media. (i) To determine swimming motility, 10 g/liter tryptone, 5 g/liter NaCl, and 0.3% (wt/vol) mid-resolution agarose was used. The plates were inoculated with an isolated colony from an overnight culture in LB agar at 37°C, using a sterile toothpick. (ii) To determine swarming motility, 1× M8 minimal medium supplemented with 1 mM MgSO4, 0.2% glucose, 0.5% Bacto Casamino Acids, and 0.5% agar. Aliquots (2.5 µl) were taken from overnight cultures to inoculate the surface of the plate. (iii) To determine twitching motility, isolated colonies were inoculated with a sterile toothpick inserted in the bottom of LB agar plates. In all cases, the plates were wrapped with film to prevent dehydration and incubated at 37°C for 16 h. After incubation, the diameter of the motility zone was measured. In the plates used to determine twitching motility, the medium was taken off the plate, and the print over the dish bottom was measured. If the area was irregular, two perpendicular diameters were measured, and the result was expressed as the mean. Ten determinations for each strain and motility type were recorded.
Invertebrate infection model.
The wax moth Galleria mellonella was used as infection model following previously described protocols (29, 30, 52). Exponentially growing cultures were pelleted, washed, and resuspended in phosphate-buffered saline (PBS). Different serial dilutions (depending on the strain) were made in PBS. A Hamilton syringe was used to inject 10-µl aliquots into individual fifth-instar G. mellonella larvae via the hindmost left proleg. Ten larvae were injected for each dilution and strain, and larvae were scored as live or dead after 24 h at 37°C. An approximate 50% lethal dose (LD50) was initially determined in a pilot screening of wide bacterial load intervals (logarithmic scale). When an approximate LD50 was obtained, three final experiments with already adjusted bacterial loads were performed. In all cases, 10 larvae were inoculated with 10 µl of PBS as controls. The percentage of larvae that had died at each bacterial dose was then analyzed by Probit analysis (53), and the LD50 ± standard deviation was finally determined using R software, version 3.2.2.
Data analysis.
With the exception of LD50s (see above), GraphPad Prism 5 software was used for graphical representation and statistical analysis. Quantitative variables were compared using Student’s t test or Mann-Whitney U test as appropriate. A P value of <0.05 was considered statistically significant.
An extended Materials and Methods section is available in the supplemental material (Text S1 in the supplemental material).
SUPPLEMENTAL MATERIAL
ACKNOWLEDGMENTS
We thank Mikael Rhen’s group (Speranta Puiac, Naeem Anwar, and Syed Fazle Rouf) for help with the experiments performed at MTC (Karolinska Institutet) and people at Smittskyddsinstitutet at the time of experimental work also (Tiziana Spadafina, Stefan Fälker, and Sandra Muschiol). We are also thankful to Victor Asensio from IdISPa for help with global transcriptomic assays.
This work was supported by the Ministerio de Economía y Competitividad of Spain and Instituto de Salud Carlos III, which were cofinanced by European Regional Development Fund “A way to achieve Europe” ERDF through the Spanish Network for the Research in Infectious Diseases (RD12/0015) and grants CP12/03324, SAF2012-38539, PI12/00103, PI15/00088, and PI15/02212.
The funders had no role in study design, data collection and interpretation or the decision to submit the work for publication.
Footnotes
Citation Pérez-Gallego M, Torrens G, Castillo-Vera J, Moya B, Zamorano L, Cabot G, Hultenby K, Albertí S, Mellroth P, Henriques-Normark B, Normark S, Oliver A, Juan C. 2016. Impact of AmpC derepression on fitness and virulence: the mechanism or the pathway? mBio 7(5):e01783-16. doi:10.1128/mBio.01783-16.
REFERENCES
- 1.Livermore DM. 2009. Has the era of untreatable infections arrived? J Antimicrob Chemother 64(Suppl 1):i29–i36. doi: 10.1093/jac/dkp255. [DOI] [PubMed] [Google Scholar]
- 2.Melnyk AH, Wong A, Kassen R. 2015. The fitness costs of antibiotic resistance mutations. Evol Appl 8:273–283. doi: 10.1111/eva.12196. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Martínez JL, Baquero F, Andersson DI. 2007. Predicting antibiotic resistance. Nat Rev Microbiol 5:958–965. doi: 10.1038/nrmicro1796. [DOI] [PubMed] [Google Scholar]
- 4.Balasubramanian D, Schneper L, Kumari H, Mathee K. 2013. A dynamic and intricate regulatory network determines Pseudomonas aeruginosa virulence. Nucleic Acids Res 41:1–20. doi: 10.1093/nar/gks1039. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Gooderham WJ, Hancock RE. 2009. Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa. FEMS Microbiol Rev 33:279–294. doi: 10.1111/j.1574-6976.2008.00135.x. [DOI] [PubMed] [Google Scholar]
- 6.Olivares J, Alvarez-Ortega C, Linares JF, Rojo F, Köhler T, Martínez JL. 2012. Overproduction of the multidrug efflux pump MexEF-OprN does not impair Pseudomonas aeruginosa fitness in competition tests, but produces specific changes in bacterial regulatory networks. Environ Microbiol 14:1968–1981. doi: 10.1111/j.1462-2920.2012.02727.x. [DOI] [PubMed] [Google Scholar]
- 7.Gellatly SL, Hancock RE. 2013. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis 67:159–173. doi: 10.1111/2049-632X.12033. [DOI] [PubMed] [Google Scholar]
- 8.Breidenstein EB, de la Fuente-Núñez C, Hancock RE. 2011. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 19:419–426. doi: 10.1016/j.tim.2011.04.005. [DOI] [PubMed] [Google Scholar]
- 9.Juan C, Maciá MD, Gutiérrez O, Vidal C, Pérez JL, Oliver A. 2005. Molecular mechanisms of beta-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 49:4733–4738. doi: 10.1128/AAC.49.11.4733-4738.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodríguez C, Moya B, Zamorano L, Suárez C, Peña C, Martínez-Martínez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI) . 2011. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother 55:1906–1911. doi: 10.1128/AAC.01645-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Normark S. 1995. Beta-lactamase induction in Gram-negative bacteria is intimately linked to peptidoglycan recycling. Microb Drug Resist 1:111–114. doi: 10.1089/mdr.1995.1.111. [DOI] [PubMed] [Google Scholar]
- 12.Johnson JW, Fisher JF, Mobashery S. 2013. Bacterial cell-wall recycling. Ann N Y Acad Sci 1277:54–75. doi: 10.1111/j.1749-6632.2012.06813.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Zhang Y, Bao Q, Gagnon LA, Huletsky A, Oliver A, Jin S, Langaee T. 2010. ampG gene of Pseudomonas aeruginosa and its role in β-lactamase expression. Antimicrob Agents Chemother 54:4772–4779. doi: 10.1128/AAC.00009-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Asgarali A, Stubbs KA, Oliver A, Vocadlo DJ, Mark BL. 2009. Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53:2274–2282. doi: 10.1128/AAC.01617-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Balcewich MD, Reeve TM, Orlikow EA, Donald LJ, Vocadlo DJ, Mark BL. 2010. Crystal structure of the AmpR effector binding domain provides insight into the molecular regulation of inducible AmpC beta-lactamase. J Mol Biol 400:998–1010. doi: 10.1016/j.jmb.2010.05.040. [DOI] [PubMed] [Google Scholar]
- 16.Jacobs C, Huang LJ, Bartowsky E, Normark S, Park JT. 1994. Bacterial cell wall recycling provides cytosolic muropeptides as effectors for beta-lactamase induction. EMBO J 13:4684–4694. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Lindberg F, Westman L, Normark S. 1985. Regulatory components in Citrobacter freundii ampC beta-lactamase induction. Proc Natl Acad Sci U S A 82:4620–4624. doi: 10.1073/pnas.82.14.4620. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Lee M, Zhang W, Hesek D, Noll BC, Boggess B, Mobashery S. 2009. Bacterial AmpD at the crossroads of peptidoglycan recycling and manifestation of antibiotic resistance. J Am Chem Soc 131:8742–8743. doi: 10.1021/ja9025566. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Lindberg F, Lindquist S, Normark S. 1987. Inactivation of the ampD gene causes semiconstitutive overproduction of the inducible Citrobacter freundii beta-lactamase. J Bacteriol 169:1923–1928. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Juan C, Moyá B, Pérez JL, Oliver A. 2006. Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cephalosporinase conferring high-level beta-lactam resistance involves three AmpD homologues. Antimicrob Agents Chemother 50:1780–1787. doi: 10.1128/AAC.50.5.1780-1787.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Moya B, Juan C, Albertí S, Pérez JL, Oliver A. 2008. Benefit of having multiple ampD genes for acquiring beta-lactam resistance without losing fitness and virulence in Pseudomonas aeruginosa. Antimicrob Agents Chemother 52:3694–3700. doi: 10.1128/AAC.00172-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Moya B, Dötsch A, Juan C, Blázquez J, Zamorano L, Haussler S, Oliver A. 2009. Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog 5:e01783-16. doi: 10.1371/journal.ppat.1000353. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Ropy A, Cabot G, Sánchez-Diener I, Aguilera C, Moya B, Ayala JA, Oliver A. 2015. Role of Pseudomonas aeruginosa low-molecular-mass penicillin-binding proteins in AmpC expression, β-lactam resistance, and peptidoglycan structure. Antimicrob Agents Chemother 59:3925–3934. doi: 10.1128/AAC.05150-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Cavallari JF, Lamers RP, Scheurwater EM, Matos AL, Burrows LL. 2013. Changes to its peptidoglycan-remodeling enzyme repertoire modulate β-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 57:3078–3084. doi: 10.1128/AAC.00268-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Lee M, Hesek D, Blázquez B, Lastochkin E, Boggess B, Fisher JF, Mobashery S. 2015. Catalytic spectrum of the penicillin-binding protein 4 of Pseudomonas aeruginosa, a nexus for the induction of β-lactam antibiotic resistance. J Am Chem Soc 137:190–200. doi: 10.1021/ja5111706. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Zamorano L, Moyà B, Juan C, Mulet X, Blázquez J, Oliver A. 2014. The Pseudomonas aeruginosa CreBC two-component system plays a major role in the response to β-lactams, fitness, biofilm growth, and global regulation. Antimicrob Agents Chemother 58:5084–5095. doi: 10.1128/AAC.02556-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Balasubramanian D, Schneper L, Merighi M, Smith R, Narasimhan G, Lory S, Mathee K. 2012. The regulatory repertoire of Pseudomonas aeruginosa AmpC β-lactamase regulator AmpR includes virulence genes. PLoS One 7:e01783-16. doi: 10.1371/journal.pone.0034067. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Zamorano L, Moyá B, Juan C, Oliver A. 2010. Differential beta-lactam resistance response driven by ampD or dacB (PBP4) inactivation in genetically diverse Pseudomonas aeruginosa strains. J Antimicrob Chemother 65:1540–1542. doi: 10.1093/jac/dkq142. [DOI] [PubMed] [Google Scholar]
- 29.Jander G, Rahme LG, Ausubel FM. 2000. Positive correlation between virulence of Pseudomonas aeruginosa mutants in mice and insects. J Bacteriol 182:3843–3845. doi: 10.1128/JB.182.13.3843-3845.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Choi JY, Sifri CD, Goumnerov BC, Rahme LG, Ausubel FM, Calderwood SB. 2002. Identification of virulence genes in a pathogenic strain of Pseudomonas aeruginosa by representational difference analysis. J Bacteriol 184:952–961. doi: 10.1128/jb.184.4.952-961.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Mikkelsen H, McMullan R, Filloux A. 2011. The Pseudomonas aeruginosa reference strain PA14 displays increased virulence due to a mutation in ladS. PLoS One 6:e01783-16. doi: 10.1371/journal.pone.0029113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Morosini MI, Ayala JA, Baquero F, Martínez JL, Blázquez J. 2000. Biological cost of AmpC production for Salmonella enterica serotype Typhimurium. Antimicrob Agents Chemother 44:3137–3143. doi: 10.1128/AAC.44.11.3137-3143.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Sauvage E, Kerff F, Terrak M, Ayala JA, Charlier P. 2008. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev 32:234–258. doi: 10.1111/j.1574-6976.2008.00105.x (Erratum, 32:556.) [DOI] [PubMed] [Google Scholar]
- 34.Zamorano L, Reeve TM, Juan C, Moyá B, Cabot G, Vocadlo DJ, Mark BL, Oliver A. 2011. AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 55:1990–1996. doi: 10.1128/AAC.01688-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Folkesson A, Eriksson S, Andersson M, Park JT, Normark S. 2005. Components of the peptidoglycan-recycling pathway modulate invasion and intracellular survival of Salmonella enterica serovar Typhimurium. Cell Microbiol 7:147–155. doi: 10.1111/j.1462-5822.2004.00443.x. [DOI] [PubMed] [Google Scholar]
- 36.Zhang W, Lee M, Hesek D, Lastochkin E, Boggess B, Mobashery S. 2013. Reactions of the three AmpD enzymes of Pseudomonas aeruginosa. J Am Chem Soc 135:4950–4953. doi: 10.1021/ja400970n. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Lee M, Artola-Recolons C, Carrasco-López C, Martínez-Caballero S, Hesek D, Spink E, Lastochkin E, Zhang W, Hellman LM, Boggess B, Hermoso JA, Mobashery S. 2013. Cell-wall remodeling by the zinc-protease AmpDh3 from Pseudomonas aeruginosa. J Am Chem Soc 135:12604–12607. doi: 10.1021/ja407445x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Martínez-Caballero S, Lee M, Artola-Recolons C, Carrasco-López C, Hesek D, Spink E, Lastochkin E, Zhang W, Hellman LM, Boggess B, Mobashery S, Hermoso JA. 2013. Reaction products and the X-ray structure of AmpDh2, a virulence determinant of Pseudomonas aeruginosa. J Am Chem Soc 135:10318–10321. doi: 10.1021/ja405464b. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Burkinshaw BJ, Deng W, Lameignère E, Wasney GA, Zhu H, Worrall LJ, Finlay BB, Strynadka NC. 2015. Structural analysis of a specialized type III secretion system peptidoglycan-cleaving enzyme. J Biol Chem 290:10406–10417. doi: 10.1074/jbc.M115.639013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Zahrl D, Wagner M, Bischof K, Bayer M, Zavecz B, Beranek A, Ruckenstuhl C, Zarfel GE, Koraimann G. 2005. Peptidoglycan degradation by specialized lytic transglycosylases associated with type III and type IV secretion systems. Microbiology 151:3455–3467. doi: 10.1099/mic.0.28141-0. [DOI] [PubMed] [Google Scholar]
- 41.Roure S, Bonis M, Chaput C, Ecobichon C, Mattox A, Barrière C, Geldmacher N, Guadagnini S, Schmitt C, Prévost MC, Labigne A, Backert S, Ferrero RL, Boneca IG. 2012. Peptidoglycan maturation enzymes affect flagellar functionality in bacteria. Mol Microbiol 86:845–856. doi: 10.1111/mmi.12019 (Erratum, 88:456–457, 2013.) [DOI] [PubMed] [Google Scholar]
- 42.Aschtgen MS, Thomas MS, Cascales E. 2010. Anchoring the type VI secretion system to the peptidoglycan: TssL, TagL, TagP … what else? Virulence 1:535–540. doi: 10.4161/viru.1.6.13732. [DOI] [PubMed] [Google Scholar]
- 43.Koebnik R. 1995. Proposal for a peptidoglycan-associating alpha-helical motif in the C-terminal regions of some bacterial cell-surface proteins. Mol Microbiol 16:1269–1270. doi: 10.1111/j.1365-2958.1995.tb02348.x. [DOI] [PubMed] [Google Scholar]
- 44.Bouveret E, Bénédetti H, Rigal A, Loret E, Lazdunski C. 1999. In vitro characterization of peptidoglycan-associated lipoprotein (PAL)-peptidoglycan and PAL-TolB interactions. J Bacteriol 181:6306–6311. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Wehbi H, Portillo E, Harvey H, Shimkoff AE, Scheurwater EM, Howell PL, Burrows LL. 2011. The peptidoglycan-binding protein FimV promotes assembly of the Pseudomonas aeruginosa type IV pilus secretin. J Bacteriol 193:540–550. doi: 10.1128/JB.01048-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Mark BL, Vocadlo DJ, Oliver A. 2011. Providing β-lactams a helping hand: targeting the AmpC β-lactamase induction pathway. Future Microbiol 6:1415–1427. doi: 10.2217/fmb.11.128 (Erratum, 7:306, 2012.) [DOI] [PubMed] [Google Scholar]
- 47.Lamers RP, Burrows LL. 2016. Pseudomonas aeruginosa: targeting cell-wall metabolism for new antibacterial discovery and development. Future Med Chem 8:975–992. doi: 10.4155/fmc-2016-0017. [DOI] [PubMed] [Google Scholar]
- 48.Jacoby GA. 2009. AmpC beta-lactamases. Clin Microbiol Rev 22:161–182. doi: 10.1128/CMR.00036-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Quénée L, Lamotte D, Polack B. 2005. Combined sacB-based negative selection and cre-lox antibiotic marker recycling for efficient gene deletion in Pseudomonas aeruginosa. BioTechniques 38:63–67. doi: 10.2144/05381ST01. [DOI] [PubMed] [Google Scholar]
- 50.Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249–264. doi: 10.1093/biostatistics/4.2.249. [DOI] [PubMed] [Google Scholar]
- 51.Mulet X, Cabot G, Ocampo-Sosa AA, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B, Peña C, Martínez-Martínez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI) . 2013. Biological markers of Pseudomonas aeruginosa epidemic high-risk clones. Antimicrob Agents Chemother 57:5527–5535. doi: 10.1128/AAC.01481-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Miyata S, Casey M, Frank DW, Ausubel FM, Drenkard E. 2003. Use of the Galleria mellonella caterpillar as a model host to study the role of the type III secretion system in Pseudomonas aeruginosa pathogenesis. Infect Immun 71:2404–2413. doi: 10.1128/IAI.71.5.2404-2413.2003 12704110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Finney DJ. 1967. Probit analysis, 2nd ed Cambridge University Press, Cambridge, United Kingdom. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.